How effective is aprecitentan (Tryvio) in lowering blood pressure? clinical data analysis

Aprocitentan-Tryvio is an endothelin A receptor antagonist with an innovative mechanism, mainly targeted at patients with refractory hypertension. In the context of limited traditional antihypertensive treatments, Tryvio has demonstrated good antihypertensive potential due to its unique action path targeting the vasoconstriction mechanism, and has become an important research hotspot in the field of international hypertension treatment in recent years.

Based on overseas data and real-world experience, Tryvio is particularly effective in reducing systolic blood pressure. Compared with traditional drugs, its antihypertensive effect is more focused on improving vascular resistance rather than through natriuresis, diuresis or inhibition of the RAAS system. This provides a new treatment perspective for multi-mechanism difficult-to-control hypertension. The mechanism of action of Tryvio is closely related to the "endothelin system activation" link in the pathogenesis of hypertension. It can target one of the core signaling pathways of vasoconstriction and improve vascular tension, especially in regulating blood pressure at night.

Some overseas studies have shown that after using Tryvio, patients’ 24-hour dynamic blood pressure curves stabilized, blood pressure fluctuations decreased, and the morning peak rise was also alleviated. Stable blood pressure is crucial for preventing events such as stroke and myocardial infarction, and this role of Tryvio is an area that traditional drugs cannot fully cover.

In addition, in some specific groups, such as patients with chronic renal insufficiency or left ventricular hypertrophy,Tryvio's blood pressure reduction is accompanied by trends such as improved vascular remodeling and reduced proteinuria, suggesting that it may have further value in "organ protection". Since Tryvio does not affect the renin-angiotensin system, its safety when used in combination with RAAS drugs is also more controllable, providing more flexibility for combination therapy.

However, it should be noted thatTryvio’s antihypertensive effect usually appears gradually after several weeks of continuous medication, and is not an immediate-acting drug. Therefore, patients should adhere to medication under the guidance of a doctor in the early stages of treatment, observe blood pressure trends, and combine it with lifestyle intervention to achieve the best effect.

Reference materials:https://go.drugbank.com/drugs/DB15059